PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:00 p.m. PT / 6:00 p.m. ET. The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be acce ...

TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aecon Group Inc. (TSX: ARE) (“Aecon” or the “Company”) announced today that its subsidiary, Aecon Utilities Group Inc. (“Aecon Utilities”), has completed the previously announced acquisition of K.P.C. Power Electrical Ltd. and K.P.C. Energy Metering Solutions Ltd. (collectively, “KPC”). “With the expanded expertise and capacity of the KPC team, we are well positioned to harness significant grid modernization, electrification and infrastructure upgrade opportunities ...

JACKSONVILLE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Regency Centers Corporation (“Regency Centers” or the “Company”) (NASDAQ: REG) will announce its fourth quarter 2025 earnings results on Thursday, February 5, 2026, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, February 6, 2026, at 11:00 a.m. E ...

CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 3:00 p.m. PT (6:00 p.m. ET). During the presentation, Dan Scavilla, President and CEO of Dentsply Sirona, will provide an update on the Company's differentiated Connected Dentistry portfolio, dental market trends and the Company’s prog ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock. All of the shares are being offered by Alumis. In addition, Alumis expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of sh ...

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors section ...

MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail supply chain cloud services, today announced that management will present at the 28th Annual Needham Growth Conference on Tuesday, January 13, 2026, at 12:45 PM E.T. A webcast of the presentation will be available on the company’s investor relations website at http://investors.spscommerce.com/events.cfm. About SPS Commerce SPS Commerce is the world’s leading retail network, connecting trading partners around ...

Core Insights - Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel molecular glue degrader (MGD)-based medicines [3] - The company will host a live conference call and webcast on January 7, 2026, to present interim clinical results from the Phase 1 study of the NEK7-directed MGD MRT-8102 [1] - The presentation will include interim data from the ongoing Part 3 CRP proof-of-concept cohort targeting subjects with elevated cardiovascular disease risk [1] Company Overview - Monte Rosa Therapeutics specializes in highly selective molecular glue degrader (MGD) medicines aimed at treating serious diseases [3] - The company's QuEEN™ discovery engine utilizes AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with high selectivity [3] - Monte Rosa has developed a leading pipeline of first-in-class and only-in-class MGDs, with three programs currently in clinical trials [3] - The company collaborates with major pharmaceutical firms in immunology, oncology, and neurology [3]

MOLINE, Ill., Jan. 06, 2026 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) (“QCRH” or the “Company”) announced today that its fourth quarter and fiscal year ended December 31, 2025 financial results will be released after the market closes on Tuesday, January 27, 2026. The Company will host a conference call and webcast the next day, Wednesday, January 28, 2026, at 10:00 a.m. Central Time to discuss the results. Shareholders, analysts, and other interested parties are invited to join. Teleconference: ...

Conference Call Wednesday, February 11th, at 11:00 A.M.RALEIGH, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) will release its fourth quarter 2025 results on Tuesday, February 10th, after the market closes. A conference call will be held the next day, Wednesday, February 11th at 11:00 A.M. Eastern time. For US/Canada callers, dial (833) 470-1428 and enter access code 568513. International callers should dial (646) 844-6383 and enter the same passcode. A live, listen-only webc ...